UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
CVKD holding history
Cadrenal Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CVKD overviewAll 13F holders of CVKDFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,112
- Value
- $3.71K
- % of portfolio
- <0.1%
- Quarters held
- 10
- Since Q1 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,112 | $3.71K | <0.1% | +1,109+36,966.7% | Added | Holders |
| Q1 2026 | 3 | $15 | <0.1% | −1,041−99.7% | Reduced | Holders |
| Q4 2025 | 1,044 | $7.08K | <0.1% | +1,009+2,882.9% | Added | Holders |
| Q3 2025 | 35 | $484 | <0.1% | −291−89.3% | Reduced | Holders |
| Q2 2025 | 326 | $3.93K | <0.1% | −8,119−96.1% | Reduced | Holders |
| Q1 2025 | 8,445 | $148.9K | <0.1% | +6,273+288.8% | Added | Holders |
| Q4 2024 | 2,172 | $31.5K | <0.1% | +2,172 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −135−100.0% | Sold out | Holders |
| Q3 2023 | 135 | $92 | <0.1% | +131+3,275.0% | Added | Holders |
| Q2 2023 | 4 | $6 | <0.1% | −226−98.3% | Reduced | Holders |
| Q1 2023 | 230 | $324 | <0.1% | +230 | New | Holders |